All Articles

The oil and gas firm raised its quarterly payout to $0.40/share, rewarding investors and underscoring its financial health and disciplined strategy.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

A new partnership makes Eli Lilly's powerful AI models available to smaller firms via Revvity's platform, aiming to accelerate innovation with federated learning.

Global investment giant Lone Star Funds acquires a second major office asset in South Florida, signaling strong confidence in the region's booming market.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Rigetti Computing pushes back its Cepheus-1-108Q launch to Q1 2026, a move that rattled investors but underscores the quantum industry's tough race for fidelity.

Koppers Holdings navigates a key leadership change as CFO Jimmi Sue Smith retires. Veteran Bradley Pearce takes the helm as interim financial chief.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

The fintech platform grew twice as fast as the overall market in 2025, fueled by tech innovation and a surge in multi-protocol trading adoption.

With a huge new investment, MEDIPOST is advancing its proven stem cell therapy for knee osteoarthritis into a pivotal Phase III trial in the United States.

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

As Encompass Health sets its Q4 earnings date, investors watch to see if the rehab giant can sustain its impressive 2025 growth amid industry pressures.

Modest growth is forecast, but Canada's economy faces a pivotal year as federal stimulus clashes with looming CUSMA renegotiations and U.S. headwinds.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

As Mammoth Biosciences preps for JPM, its ultracompact CRISPR tech aims to redefine in vivo gene therapy, promising cures for diseases beyond the liver.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

Private equity giant Bain Capital and BlueWater Marinas acquire Kent Narrows Boatel, signaling a new wave of investment in the luxury boating market.

Raleigh-based Attindas Hygiene Partners acquires 53-year-old Italian firm SILC, a strategic move to capture a larger share of Europe's booming hygiene market.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.